Key Points
- Insider sale: 4D Molecular Therapeutics insider David Kirn sold 1,922 shares on June 1 at an average price of $10.02, totaling about $19,258. After the transaction, he still owned 1,057,231 shares.
- Stock and earnings update: FDMT was trading around $9.27, down 4.5%, after reporting a first-quarter loss of $1.01 per share, which missed analyst expectations. Revenue came in at $3.05 million, above estimates.
- Analyst sentiment remains mixed but mostly positive: Seven analysts rate the stock a Buy, one a Hold, and one a Sell, with a consensus target of $29.88. However, one recent report downgraded the stock to Sell while others maintained or reiterated bullish ratings.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider David Kirn sold 1,922 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $10.02, for a total transaction of $19,258.44. Following the sale, the insider directly owned 1,057,231 shares in the company, valued at $10,593,454.62. This trade represents a 0.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
4D Molecular Therapeutics Trading Down 4.5%
Shares of FDMT opened at $9.27 on Wednesday. The stock has a market capitalization of $484.64 million, a P/E ratio of -3.61 and a beta of 2.75. The firm's fifty day simple moving average is $9.53 and its two-hundred day simple moving average is $9.28. 4D Molecular Therapeutics, Inc. has a 12 month low of $3.68 and a 12 month high of $12.34.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.74 EPS for the current fiscal year.
Institutional Investors Weigh In On 4D Molecular Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth about $41,000. Daiwa Securities Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company's stock worth $48,000 after acquiring an additional 6,186 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth about $80,000. Susquehanna Portfolio Strategies LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $77,000. Finally, Martingale Asset Management L P raised its holdings in shares of 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company's stock worth $88,000 after acquiring an additional 1,303 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts have commented on FDMT shares. Royal Bank Of Canada upped their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, March 19th. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Jefferies Financial Group reissued a "buy" rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.88.
View Our Latest Report on FDMT
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
